{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:29:05Z","timestamp":1790173745294,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to predict and monitor treatment response, cancer and angiogenesis relevant mutations in tumour and circulating tumour DNA (ctDNA) were investigated in 26 metastatic melanoma patients treated with bevacizumab. Patients with &gt;1% <jats:italic>BRAF\/NRAS<\/jats:italic> ctDNA at treatment start had significantly decreased progression free survival (PFS) and overall survival (OS) (PFS: p\u2009=\u20090.019, median 54 vs 774 days, OS: p\u2009=\u20090.026, median 209 vs 1064 days). Patients with &gt;1% <jats:italic>BRAF\/NRAS<\/jats:italic> ctDNA during treatment showed similar results (PFS: p\u2009=\u20090.002, OS: p\u2009=\u20090.003). \u22641% <jats:italic>BRAF\/NRAS<\/jats:italic> ctDNA and normal lactate dehydrogenase (LDH) levels both significantly predicted increased response to treatment, but <jats:italic>BRAF\/NRAS<\/jats:italic> ctDNA was better at predicting response compared to LDH at treatment start (OR 16.94, p\u2009=\u20090.032 vs OR 4.57, p\u2009=\u20090.190), and at predicting PFS (HR 6.76, p\u2009=\u20090.002) and OS (HR 6.78, p\u2009=\u20090.002) during therapy. ctDNA <jats:italic>BRAF<\/jats:italic> p.V600D\/E\/K and <jats:italic>NRAS<\/jats:italic> p.G12V\/p.Q61K\/L\/R were better biomarkers for response prediction than <jats:italic>TERT<\/jats:italic> promoter mutations (OR 1.50, p\u2009=\u20090.657). Next generation sequencing showed that all patients with \u22652 mutations in angiogenesis-relevant genes had progressive disease, but did not reveal other biomarkers identifying responders. To conclude, ctDNA and LDH are useful biomarkers for both monitoring and predicting response to bevacizumab.<\/jats:p>","DOI":"10.1038\/s41598-019-53917-5","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T11:02:49Z","timestamp":1574679769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab"],"prefix":"10.1038","volume":"9","author":[{"given":"Rakel Brendsdal","family":"Forthun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Hovland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Puntervoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Petter","family":"Brodal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi Maria","family":"Naml\u00f8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Birger","family":"Aasheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo A.","family":"Meza-Zepeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-9704","authenticated-orcid":false,"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stian","family":"Knappskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oddbj\u00f8rn","family":"Straume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"53917_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","volume":"404","author":"L Calapre","year":"2017","unstructured":"Calapre, L., Warburton, L., Millward, M., Ziman, M. & Gray, E. S. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett 404, 62\u201369, https:\/\/doi.org\/10.1016\/j.canlet.2017.06.030 (2017).","journal-title":"Cancer Lett"},{"key":"53917_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","volume":"164","author":"JH Lee","year":"2011","unstructured":"Lee, J. H., Choi, J. W. & Kim, Y. S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164, 776\u2013784, https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10185.x (2011).","journal-title":"Br J Dermatol"},{"key":"53917_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957\u2013959, https:\/\/doi.org\/10.1126\/science.1229259 (2013).","journal-title":"Science"},{"key":"53917_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.384","author":"E Hugdahl","year":"2017","unstructured":"Hugdahl, E., Kalvenes, M. B., Mannelqvist, M., Ladstein, R. G. & Akslen, L. A. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma. Br J Cancer. https:\/\/doi.org\/10.1038\/bjc.2017.384 (2017).","journal-title":"Br J Cancer"},{"key":"53917_CR5","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.1158\/1078-0432.CCR-17-0980","volume":"23","author":"X Bai","year":"2017","unstructured":"Bai, X. et al. MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clin Cancer Res 23, 6120\u20136127, https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0980 (2017).","journal-title":"Clin Cancer Res"},{"key":"53917_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep45704","volume":"7","author":"B Seynnaeve","year":"2017","unstructured":"Seynnaeve, B. et al. Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma. Sci Rep 7, 45704, https:\/\/doi.org\/10.1038\/srep45704 (2017).","journal-title":"Sci Rep"},{"key":"53917_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ijc.30042","volume":"139","author":"E Nagore","year":"2016","unstructured":"Nagore, E. et al. TERT promoter mutations in melanoma survival. Int J Cancer 139, 75\u201384, https:\/\/doi.org\/10.1002\/ijc.30042 (2016).","journal-title":"Int J Cancer"},{"key":"53917_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3, 391\u2013400, https:\/\/doi.org\/10.1038\/nrd1381 (2004).","journal-title":"Nat Rev Drug Discov"},{"key":"53917_CR9","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/annonc\/mdy229","volume":"29","author":"PG Corrie","year":"2018","unstructured":"Corrie, P. G. et al. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of oncology: official journal of the European Society for Medical Oncology 29, 1843\u20131852, https:\/\/doi.org\/10.1093\/annonc\/mdy229 (2018).","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"53917_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cjp2.116","volume":"5","author":"C Schuster","year":"2019","unstructured":"Schuster, C., Akslen, L. A., Stokowy, T. & Straume, O. Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. J Pathol Clin Res 5, 53\u201362, https:\/\/doi.org\/10.1002\/cjp2.116 (2019).","journal-title":"J Pathol Clin Res"},{"key":"53917_CR11","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/cas.13098","volume":"107","author":"K Shitara","year":"2016","unstructured":"Shitara, K. et al. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci 107, 1843\u20131850, https:\/\/doi.org\/10.1111\/cas.13098 (2016).","journal-title":"Cancer Sci"},{"key":"53917_CR12","doi-asserted-by":"publisher","first-page":"e38364","DOI":"10.1371\/journal.pone.0038364","volume":"7","author":"C Schuster","year":"2012","unstructured":"Schuster, C. et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One 7, e38364, https:\/\/doi.org\/10.1371\/journal.pone.0038364 (2012).","journal-title":"PLoS One"},{"key":"53917_CR13","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/sj.onc.1206101","volume":"22","author":"MS Greenblatt","year":"2003","unstructured":"Greenblatt, M. S. et al. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene 22, 1150\u20131163, https:\/\/doi.org\/10.1038\/sj.onc.1206101 (2003).","journal-title":"Oncogene"},{"key":"53917_CR14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.18632\/oncotarget.577","volume":"3","author":"G Jin","year":"2012","unstructured":"Jin, G. et al. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget 3, 774\u2013782, https:\/\/doi.org\/10.18632\/oncotarget.577 (2012).","journal-title":"Oncotarget"},{"key":"53917_CR15","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1002\/cncr.28271","volume":"119","author":"C Colombo","year":"2013","unstructured":"Colombo, C. et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 119, 3696\u20133702, https:\/\/doi.org\/10.1002\/cncr.28271 (2013).","journal-title":"Cancer"},{"key":"53917_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/sj.onc.1200870","volume":"14","author":"W Arap","year":"1997","unstructured":"Arap, W., Knudsen, E. S., Wang, J. Y., Cavenee, W. K. & Huang, H. J. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)\/CDKN2A in human glioma. Oncogene 14, 603\u2013609, https:\/\/doi.org\/10.1038\/sj.onc.1200870 (1997).","journal-title":"Oncogene"},{"key":"53917_CR17","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev 26, 1268\u20131286, https:\/\/doi.org\/10.1101\/gad.190678.112 (2012).","journal-title":"Genes Dev"},{"key":"53917_CR18","doi-asserted-by":"publisher","first-page":"11003","DOI":"10.1073\/pnas.0604507103","volume":"103","author":"W Wang","year":"2006","unstructured":"Wang, W., Kim, S. H. & El-Deiry, W. S. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proceedings of the National Academy of Sciences of the United States of America 103, 11003\u201311008, https:\/\/doi.org\/10.1073\/pnas.0604507103 (2006).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"53917_CR19","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1073\/pnas.0813333106","volume":"106","author":"S Sur","year":"2009","unstructured":"Sur, S. et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proceedings of the National Academy of Sciences of the United States of America 106, 3964\u20133969, https:\/\/doi.org\/10.1073\/pnas.0813333106 (2009).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"53917_CR20","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1038\/onc.2011.29","volume":"30","author":"FI Nazeer","year":"2011","unstructured":"Nazeer, F. I. et al. p53 inhibits mRNA 3\u2032 processing through its interaction with the CstF\/BARD1 complex. Oncogene 30, 3073\u20133083, https:\/\/doi.org\/10.1038\/onc.2011.29 (2011).","journal-title":"Oncogene"},{"key":"53917_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1073\/pnas.1220895110","volume":"110","author":"MJ Davis","year":"2013","unstructured":"Davis, M. J. et al. RAC1P29S is a spontaneously activating cancer-associated GTPase. Proceedings of the National Academy of Sciences of the United States of America 110, 912\u2013917, https:\/\/doi.org\/10.1073\/pnas.1220895110 (2013).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"53917_CR22","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/pcmr.12392","volume":"28","author":"HL Vu","year":"2015","unstructured":"Vu, H. L., Rosenbaum, S., Purwin, T. J., Davies, M. A. & Aplin, A. E. RAC1 P29S regulates PD-L1 expression in melanoma. Pigment Cell Melanoma Res 28, 590\u2013598, https:\/\/doi.org\/10.1111\/pcmr.12392 (2015).","journal-title":"Pigment Cell Melanoma Res"},{"key":"53917_CR23","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1158\/0008-5472.CAN-14-1232-T","volume":"74","author":"IR Watson","year":"2014","unstructured":"Watson, I. R. et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res 74, 4845\u20134852, https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1232-T (2014).","journal-title":"Cancer Res"},{"key":"53917_CR24","doi-asserted-by":"publisher","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","volume":"7","author":"M Yancovitz","year":"2012","unstructured":"Yancovitz, M. et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One 7, e29336, https:\/\/doi.org\/10.1371\/journal.pone.0029336 (2012).","journal-title":"PLoS One"},{"key":"53917_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2992-8","volume":"17","author":"HM Namlos","year":"2017","unstructured":"Namlos, H. M. et al. Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report. BMC cancer 17, 29, https:\/\/doi.org\/10.1186\/s12885-016-2992-8 (2017).","journal-title":"BMC cancer"},{"key":"53917_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263, https:\/\/doi.org\/10.1016\/j.cell.2012.06.024 (2012).","journal-title":"Cell"},{"key":"53917_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1541-7786.mcr-13-0422","volume":"12","author":"HL Gold","year":"2014","unstructured":"Gold, H. L. et al. PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition. Molecular cancer research: MCR 12, 433\u2013439, https:\/\/doi.org\/10.1158\/1541-7786.mcr-13-0422 (2014).","journal-title":"Molecular cancer research: MCR"},{"key":"53917_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17, 223\u2013238, https:\/\/doi.org\/10.1038\/nrc.2017.7 (2017).","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"53917_CR29","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/1878-0261.12561","volume":"13","author":"Evita Maria Lindholm","year":"2019","unstructured":"Lindholm, E. M. et al. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Mol Oncol, https:\/\/doi.org\/10.1002\/1878-0261.12561 (2019).","journal-title":"Molecular Oncology"},{"key":"53917_CR30","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404\u20132415, https:\/\/doi.org\/10.1016\/S0140-6736(19)30723-8 (2019).","journal-title":"Lancet"},{"key":"53917_CR31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00262-019-02317-9","volume":"68","author":"V Quillien","year":"2019","unstructured":"Quillien, V. et al. Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients. Cancer Immunol Immunother 68, 871\u2013882, https:\/\/doi.org\/10.1007\/s00262-019-02317-9 (2019).","journal-title":"Cancer Immunol Immunother"},{"key":"53917_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.clcc.2018.11.004","volume":"18","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio, F. et al. Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. Clin Colorectal Cancer 18, 34\u201343 e36, https:\/\/doi.org\/10.1016\/j.clcc.2018.11.004 (2019).","journal-title":"Clin Colorectal Cancer"},{"key":"53917_CR33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ygyno.2018.08.027","volume":"151","author":"WP Tew","year":"2018","unstructured":"Tew, W. P. et al. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology\/gynecologic oncology group study. Gynecol Oncol 151, 257\u2013263, https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.027 (2018).","journal-title":"Gynecol Oncol"},{"key":"53917_CR34","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.18632\/oncotarget.23989","volume":"9","author":"MC Sini","year":"2018","unstructured":"Sini, M. C. et al. Genetic alterations in main candidate genes during melanoma progression. Oncotarget 9, 8531\u20138541, https:\/\/doi.org\/10.18632\/oncotarget.23989 (2018).","journal-title":"Oncotarget"},{"key":"53917_CR35","doi-asserted-by":"publisher","first-page":"5986129","DOI":"10.1155\/2017\/5986129","volume":"2017","author":"B Busser","year":"2017","unstructured":"Busser, B. et al. Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. Biomed Res Int 2017, 5986129, https:\/\/doi.org\/10.1155\/2017\/5986129 (2017).","journal-title":"Biomed Res Int"},{"key":"53917_CR36","doi-asserted-by":"publisher","unstructured":"Wong, S. Q. et al. Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. 1-14, https:\/\/doi.org\/10.1200\/po.16.00009 (2017).","DOI":"10.1200\/po.16.00009"},{"key":"53917_CR37","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray, E. S. et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6, 42008\u201342018, https:\/\/doi.org\/10.18632\/oncotarget.5788 (2015).","journal-title":"Oncotarget"},{"key":"53917_CR38","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of oncology: official journal of the European Society for Medical Oncology 28, 1130\u20131136, https:\/\/doi.org\/10.1093\/annonc\/mdx026 (2017).","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"53917_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem, S. et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114, 256\u2013261, https:\/\/doi.org\/10.1038\/bjc.2015.467 (2016).","journal-title":"Br J Cancer"},{"key":"53917_CR40","doi-asserted-by":"publisher","first-page":"25265","DOI":"10.18632\/oncotarget.25404","volume":"9","author":"G Herbreteau","year":"2018","unstructured":"Herbreteau, G. et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget 9, 25265\u201325276, https:\/\/doi.org\/10.18632\/oncotarget.25404 (2018).","journal-title":"Oncotarget"},{"key":"53917_CR41","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.intimp.2016.09.030","volume":"40","author":"J Felix","year":"2016","unstructured":"Felix, J. et al. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. Int Immunopharmacol 40, 466\u2013473, https:\/\/doi.org\/10.1016\/j.intimp.2016.09.030 (2016).","journal-title":"Int Immunopharmacol"},{"key":"53917_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.molonc.2015.09.005","volume":"10","author":"GA Chang","year":"2016","unstructured":"Chang, G. A. et al. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol 10, 157\u2013165, https:\/\/doi.org\/10.1016\/j.molonc.2015.09.005 (2016).","journal-title":"Mol Oncol"},{"key":"53917_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep11198","volume":"5","author":"SC Tsao","year":"2015","unstructured":"Tsao, S. C. et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep 5, 11198, https:\/\/doi.org\/10.1038\/srep11198 (2015).","journal-title":"Sci Rep"},{"key":"53917_CR44","doi-asserted-by":"publisher","first-page":"78890","DOI":"10.18632\/oncotarget.20354","volume":"8","author":"AC McEvoy","year":"2017","unstructured":"McEvoy, A. C. et al. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget 8, 78890\u201378900, https:\/\/doi.org\/10.18632\/oncotarget.20354 (2017).","journal-title":"Oncotarget"},{"key":"53917_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/1878-0261.12391","volume":"13","author":"L Calapre","year":"2019","unstructured":"Calapre, L. et al. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Mol Oncol 13, 171\u2013184, https:\/\/doi.org\/10.1002\/1878-0261.12391 (2019).","journal-title":"Mol Oncol"},{"key":"53917_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss, M. et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun 8, 1738, https:\/\/doi.org\/10.1038\/s41467-017-01460-0 (2017).","journal-title":"Nat Commun"},{"key":"53917_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165, 35\u201344, https:\/\/doi.org\/10.1016\/j.cell.2016.02.065 (2016).","journal-title":"Cell"},{"key":"53917_CR48","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.2359","volume":"44","author":"M Krauthammer","year":"2012","unstructured":"Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44, 1006\u20131014, https:\/\/doi.org\/10.1038\/ng.2359 (2012).","journal-title":"Nat Genet"},{"key":"53917_CR49","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.bbrc.2010.06.125","volume":"398","author":"GY Lopez","year":"2010","unstructured":"Lopez, G. Y. et al. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun 398, 585\u2013587, https:\/\/doi.org\/10.1016\/j.bbrc.2010.06.125 (2010).","journal-title":"Biochem Biophys Res Commun"},{"key":"53917_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/his.13707","author":"K Linos","year":"2018","unstructured":"Linos, K. & Tafe, L. J. Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations. Histopathology. https:\/\/doi.org\/10.1111\/his.13707 (2018).","journal-title":"Histopathology"},{"key":"53917_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/JBM.S70716","volume":"7","author":"J Mondesir","year":"2016","unstructured":"Mondesir, J., Willekens, C., Touat, M. & de Botton, S. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med 7, 171\u2013180, https:\/\/doi.org\/10.2147\/JBM.S70716 (2016).","journal-title":"J Blood Med"},{"key":"53917_CR52","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11899-017-0418-6","volume":"12","author":"BK Ragon","year":"2017","unstructured":"Ragon, B. K. & DiNardo, C. D. Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia. Curr Hematol Malig Rep 12, 537\u2013546, https:\/\/doi.org\/10.1007\/s11899-017-0418-6 (2017).","journal-title":"Curr Hematol Malig Rep"},{"key":"53917_CR53","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/1878-0261.12373","volume":"12","author":"SP Rowe","year":"2018","unstructured":"Rowe, S. P. et al. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol 12, 1661\u20131672, https:\/\/doi.org\/10.1002\/1878-0261.12373 (2018).","journal-title":"Mol Oncol"},{"key":"53917_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4637-6","volume":"18","author":"AC McEvoy","year":"2018","unstructured":"McEvoy, A. C. et al. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC cancer 18, 726, https:\/\/doi.org\/10.1186\/s12885-018-4637-6 (2018).","journal-title":"BMC cancer"},{"key":"53917_CR55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92, 205\u2013216 (2000).","journal-title":"J Natl Cancer Inst"},{"key":"53917_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/CMR.0b013e3282f32517","volume":"18","author":"LA Akslen","year":"2008","unstructured":"Akslen, L. A. et al. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18, 29\u201335, https:\/\/doi.org\/10.1097\/CMR.0b013e3282f32517 (2008).","journal-title":"Melanoma Res"},{"key":"53917_CR57","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954, https:\/\/doi.org\/10.1038\/nature00766 (2002).","journal-title":"Nature"},{"key":"53917_CR58","first-page":"6483","volume":"9","author":"K Omholt","year":"2003","unstructured":"Omholt, K., Platz, A., Kanter, L., Ringborg, U. & Hansson, J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9, 6483\u20136488 (2003).","journal-title":"Clin Cancer Res"},{"key":"53917_CR59","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nature medicine 21, 751\u2013759, https:\/\/doi.org\/10.1038\/nm.3886 (2015).","journal-title":"Nature medicine"},{"key":"53917_CR60","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics (Oxford, England) 26, 589\u2013595, https:\/\/doi.org\/10.1093\/bioinformatics\/btp698 (2010).","journal-title":"Bioinformatics (Oxford, England)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53917-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53917-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:24:09Z","timestamp":1671294249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53917-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53917"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53917-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17471"}}